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Abstract
Mycobacterium kansasii has emerged as an important nontuberculous mycobacterium pathogen, whose incidence and
prevalence have been increasing in the last decade. M. kansasii can cause pulmonary tuberculosis clinically and
radiographically indistinguishable from that caused by Mycobacterium tuberculosis infection. Unlike the widely-studied M.
tuberculosis, little is known about the innate immune response against M. kansasii infection. Although inflammasome
activation plays an important role in host defense against bacterial infection, its role against atypical mycobacteria remains
poorly understood. In this report, the role of inflammasome activity in THP-1 macrophages against M. kansasii infection was
studied. Results indicated that viable, but not heat-killed, M. kansasii induced caspase-1-dependent IL-1b secretion in
macrophages. The underlying mechanism was found to be through activation of an inflammasome containing the NLR
(Nod-like receptor) family member NLRP3 and the adaptor protein ASC (apoptosis-associated speck-like protein containing
a CARD). Further, potassium efflux, lysosomal acidification, ROS production and cathepsin B release played a role in M.
kansasii-induced inflammasome activation. Finally, the secreted IL-1b derived from caspase-1 activation was shown to
restrict intracellular M. kansasii. These findings demonstrate a biological role for the NLRP3 inflammasome in host defense
against M. kansasii.
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Introduction
Mycobacterium kansasii is an acid-fast bacillus that has emerged as
an important pathogen of the group of nontuberculous mycobac-
teria (NTM). It is the second most-common nontuberculous
opportunistic mycobacterial infection linked with AIDS, surpassed
only by Mycobacterium avium complex (MAC) [1–3]. Furthermore,
M. kansasii infects both immunocompetent and immunocompro-
mised patients [4–9].
Although geographical variability of infection exists, M. kansasii
is the most common cause of NTM-induced lung diseases in the
United Kingdom and Western Europe [10–14]. M. kansasii causes
pulmonary infection that resembles tuberculosis clinically and
radiographically and is indistinguishable from Mycobacterium
tuberculosis infection [12,13,15]. Comorbidity diseases are frequent-
ly closely related with M. kansasii pulmonary infection, including
chronic obstructive pulmonary disease, bronchiectasis, pneumo-
noconiosis, previous tuberculosis, or carcinoma [16,17]. In
addition, extrapulmonary infection of M. kansasii can cause
gastroenteritis, lymphadenitis, osteomyelitis, synovitis, cellulitis,
empyema or pericarditis [14,18,19]. Furthermore, disseminated
M. kansasii infections also commonly occur, especially in
immunocompromised patients with advanced AIDS [20,21].
Comparatively, unlike the widely-studied M. tuberculosis, most
reports on M. kansasii focus on epidemiological and clinical
features of infection [22–24]. Little is known about the innate
immune response against M. kansasii infection.
Macrophages represent the first line of host defense against most
bacterial pathogens. Following interaction with the bacteria,
macrophages initiate inflammatory responses by secreting cyto-
kines and chemokines [25,26]. Among these, one of the key
proinflammatory cytokines for antimicrobial responses is interleu-
kin-1b (IL-1b) [27]. Two signaling systems control the synthesis,
processing and secretion of IL-1b. Pathogen-recognition receptors
such as Toll-like receptors (TLRs) control synthesis of pro-IL-1b,
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and the nucleotide binding and oligomerization domain (NOD)-
like receptors (NLRs) lead to inflammasome activation and IL-1b
maturation and secretion [28].
During infection with pathogenic bacteria, assembly and
activation of the inflammasome result in caspase-1 activation
and IL-1b secretion, which are critical for an effective immune
response [29]. To date, among the four major inflammasomes
described [30], the most thoroughly characterized is the NLRP3
inflammasome, which is activated by a number of diverse stimuli,
including whole pathogens, microbial components and danger
signals [31]. Upon activation, NLRP3 oligomerizes and recruits
the adaptor protein ASC (apoptosis-associated speck-like protein
containing a CARD) through pyrin domain interactions. In turn,
procaspase-1 is recruited by ASC via CARD-CARD interactions,
thus forming the NLRP3 inflammasome and leading to caspase-1
activation. Caspase-1 is synthesized as a 45 kDa precursor (p45)
before being cleaved into 20 kDa (p20) and 10 kDa (p10) mature
proteins that form a hetero-tetrameric complex that express the
enzymatic activity [32]. Thus, the appearance of p20 and p10 in
culture supernatants reflects caspase-1 activation [33]. Similarly,
upon stimulation of a pathogen recognition receptor such as the
TLRs, proinflammatory cytokine IL-1b is generated as a 31 kDa
proform which is proteolytically processed to the biologically
active 17 kDa form by caspase-1 [34], and then released into the
extracellular space through mechanisms that remain poorly
characterized [35,36].
Previous studies have indicated that M. marinum and M.
tuberculosis and their components can activate an inflammasome
consisting of NLRP3 and ASC [37,38]. In addition to live M.
tuberculosis, the ESAT-6 protein from the mycobacteria has been
shown to induce activation of NLRP3/ASC inflammasome
maturation and release of IL-1b from THP-1 macrophages [39].
Furthermore, studies using primary macrophages demonstrated
that M. marinum activates the NLRP3/ASC inflammasome in an
ESX-1-dependent manner [40]. Recently, a rapidly growing
NTM, M. abscessus, has been reported to activate the NLRP3/
ASC inflammasome via dectin-1/Syk-dependent signaling and the
cytoplasmic scaffold protein p62/SQSTM1 in human macro-
phages [41]. However, whether M. kansasii, a slowly growing
NTM, infection could induce caspase-1 activation and IL-1b
secretion via the inflammasome activation has not been reported
yet. Therefore, the role of inflammasome activation and secretion
of IL-1b in prevention of M. kansasii infection was addressed in this
study. Using the human macrophage cell line THP-1, we
demonstrated that live intracellular M. kansasii triggers the
activation of the NLRP3/ASC complex, caspase-1 activation,
and IL-1b secretion. We further showed that potassium efflux,
lysosomal acidification, cathepsin B release and production of
reactive oxygen species (ROS) are required for the activation of
the inflammasome. Finally, we demonstrate a major role for the
secreted IL-1b in controlling M. kansasii infection. These results
demonstrate an important biological function for the NLRP3
inflammasome in host defense against M. kansasii infection.
Results
Live intracellular M. kansasii triggers caspase-1 activation
and IL-1b secretion in macrophages
To determine whether M. kansasii infection could induce
caspase-1 activation and IL-1b secretion, THP-1 macrophages
were challenged with M. kansasii at various multiplicities of
infection (MOI) for 16 h. Caspase-1 cleavage and IL-1b
processing were analyzed by ELISA and immunoblotting.
Compared to untreated cells, bacterial challenge resulted in a
dose-dependent caspase-1 activation and IL-1b secretion
(Figure 1A and B), indicating that M. kansasii infection activates
caspase-1 and promotes IL-1b release. By contrast, heat-killed M.
kansasii failed to induce caspase-1 activation nor IL-1b secretion
(Figure 1C). As macrophages can engulf mycobacteria, whether
internalization of M. kansasii is required for the processing of IL-1b
and caspase-1 was examined. Cytochalasin D, an inhibitor of actin
polymerization, was used to block phagocytosis before M. kansasii
infection. As shown in Figure 1D, caspase-1 activation and IL-1b
maturation were abolished when internalization of M. kansasii by
macrophages was inhibited. To determine whether activated
caspase-1 is responsible for M. kansasii induced maturation and
secretion of IL-1b, macrophages were pretreated with Z-YVAD-
FMK, a cell-permeable and irreversible caspase-1 inhibitor. When
caspase-1 activity was inhibited, the release of mature IL-1b into
supernatants was reduced in a dose dependent manner, and both
IL-1b processing and caspase-1 activation were reduced (Figure 2).
Thus, viable intracellular M. kansasii induce caspase-1-dependent
IL-1b secretion from macrophages.
The NLRP3/ASC inflammasome contributes to caspase-1
activation and IL-1b secretion during M. kansasii infection
To define the role of NLRP3 inflammasome components in
activation of caspase-1 by M. kansasii infection, NLRP3 or ASC in
THP-1 cells were depleted by shRNA. Compared to non-target
shRNA control, mRNA and protein levels of NLRP3 or ASC in
the respective knockdown cells were significantly reduced
(Figure 3A). NLRP3, ASC, or nontarget control knockdown
THP-1 cells were then challenged withM. kansasii at an MOI of 10
for 16 h, and caspase-1 activation was revealed by the appearance
of caspase-1 p20 and IL-1b p17 in Western blots. When compared
to non-target control cells, depletion of either NLRP3 or ASC
caused a significant reduction in the amount of secreted IL-
1b(Figure 3B), while IL-6 production was unimpaired (Figure S1).
Concomitantly, significant reduction of caspase-1 p20 levels was
also observed (Figure 3C). Taken together, the results show that
NLRP3 and ASC are required for M. kansasii induced caspase-1
activation and IL-1b processing in macrophages.
Potassium efflux, lysosomal acidification, ROS production
and cathepsin B release are involved in M. kansasii-
induced inflammasome activation
Previous studies have reported a number of signaling mecha-
nisms playing important roles in activating the NLRP3/ASC
inflammasome, including potassium efflux, lysosomal acidification,
generation of reactive oxygen species (ROS) and cathepsin B
release from lysosomes. To explore whether any of these factors
are involved in M. kansasii-induced inflammasome activation, a
series of defined inhibitors were used to treat M. kansasii-
challenged THP-1 macrophages. The amount of secreted IL-1b
in culture supernatants was used as an indicator of inflammasome
activation. A high extracellular potassium concentration (130 mM)
was first used to test if inhibiting K+ efflux can influence M.
kansasii-mediated activation of the NLRP3/ASC inflammasome.
Following infection of THP-1 macrophages in high extracellular
[K+], M. kansasii-induced IL-1b release was significantly inhibited
(Figure 4A). Moreover, glibenclamide, a selective inhibitor for
ATP-dependent potassium channels, was used to block potassium
efflux. Addition of 50 mM glibenclamide to macrophages prior to
bacterial challenge significantly reduced IL-1b secretion
(Figure 4A). Since ROS generation was reported to activate the
NLRP3/ASC inflammasome [42], the anti-oxidant, N-acetyl
cysteine (NAC), was used to determine whether ROS are involved
NLRP3 Restricts Mycobacterium kansasii Infection
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in M. kansasii-mediated NLRP3/ASC inflammasome activation.
IL-1b secretion was significantly reduced upon treatment with
25 mM NAC (Figure 4B), indicating that ROS also contributes to
NLRP3/ASC inflammasome activation during M. kansasii infec-
tion. As the NLRP3 inflammasome can be activated due to
lysosomal damage and release of cathepsin B, ammonium chloride
(NH4Cl) and chloroquine diphosphate (CQ), which inhibit
endosomal-lysosomal system acidification, and CA-074-Me, which
acts as a cell-permeable inhibitor of thiol proteases, were used to
block lysosomal acidification and cathepsin B activity, respectively.
The three inhibitors resulted in a significant reduction in IL-1b
release after M. kansasii challenge (Figure 4C), suggesting a role for
lysosomes in NLRP3/ASC inflammasome activation in response
to M. kansasii infection. However, these marked inhibitory effects
were not due to cytotoxicity from these treatments (Fig S2). Thus,
the results suggest that NLRP3/ASC activation during M. kansasii
infection involves most of the pathways known to activate the
Figure 1. Live intracellular M. kansasii activates caspase-1 and induces IL-1b secretion in THP-1 derived macrophages. Macrophages
were infected by M. kansasii, followed by analysis of caspase-1 activation and IL-1bsecretion in culture media. (A) The amount of IL-1b secreted from
infected macrophages at an MOI of 0.1–10 for 16 h. (B) The secreted mature caspase-1 and IL-1b from infected macrophages at an MOI of 0.1–25 for
16 h. (C) Macrophages were challenged with live or heat-killedM. kansasii at an MOI of 10 for 16 h. Secreted IL-1b was measured by ELISA (left panel).
Caspase-1 p20 and 17-kDa IL-1b were analyzed by immunoblotting (right panel). (D) Macrophages were treated with 1 mg/ml CytoD for 60 min to
block phagocytosis and then incubated with M. kansasii at an MOI of 10 in the presence or absence of CytoD. Secreted IL-1b was measured by ELISA
(left panel); activated caspase-1 and mature IL-1b were detected by Western blot analysis (right panel). Cells treated with 1 mg/ml LPS for 3 h and
1 mM nigericin for 1.5 h were used as control (LPS+Nig). Values represent the mean6 standard deviations of at least three independent experiments.
doi:10.1371/journal.pone.0036292.g001
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NLRP3 inflammasome: potassium efflux, lysosomal acidification,
cathepsin B release, and ROS production.
IL-1b derived from caspase-1 activation restricts M.
kansasii infection
Caspase-1 activation has been reported to restrict bacterial
infection either directly, by affecting bacterial growth, or
indirectly, through IL-1b-mediated inhibition of infection
[38,39,43–46]. To address the contribution of caspase-1 in the
control of M. kansasii infection, macrophages were treated with
caspase-1 inhibitor, Z-YVAD-FMK, before M. kansasii challenge.
Intracellular bacterial growth was evaluated by quantifying the
colony forming units (CFUs) for 96 h following bacterial infection.
The number of CFUs recovered from macrophages treated with
caspase-1 inhibitor was greater than those from untreated cells,
indicating that caspase-1 activation contributes to control of M.
kansasii infection in macrophages (Figure 5A).
Studies from knockout mice with deficiency in either IL-1b or
its receptor, IL-1R, suggested that IL-1b plays an important role in
the immune response to M. tuberculosis or M. kansasii infection in
mice [47–49]. Whether IL-1b also affects M. kansasii infection of
human macrophages in vitro was next investigated. THP-1
macrophages were treated with IL-1b neutralizing antibody
during bacterial infection. The intracellular bacterial number
was evaluated by quantifying the CFUs at 48 h post-infection.
Blocking IL-1b signaling with IL-1b specific neutralizing antibody
resulted in a nearly 5-fold increase in the number of intracellular
M. kansasii (Figure 5B). Conversely, exogenously-added IL-
1bsignificantly reduced the bacterial counts in macrophages.
These results suggest that IL-1b secreted due to NLRP3
inflammasome activation is critical for the control of intracellular
M. kansasii, and that caspase-1 most likely affects infection
indirectly, through processing of IL-1b.
Discussion
In this report, we demonstrated that live and intracellular M.
kansasii can trigger caspase-1 activation and IL-1b secretion from
human macrophages by activating the NLRP3/ASC inflamma-
some. Heat-killed and extracellular M. kansasii failed to activate the
NLRP3/ASC inflammasome, suggesting that simple surface
contact of M. kansasii with macrophages is not sufficient for
activation of the inflammasome. Although the precise mechanisms
behind responsible for NLRP3/ASC inflammasome activation are
still under investigation, our results suggest that M. kansasii
infection of macrophages can induce potassium efflux, cathepsin
B release and ROS production, all of which are involved in
NLRP3/ASC inflammasome activation. Additionally, the results
from the intracellular survival assay revealed that M. kansasii-
induced caspase-1 activation and subsequent IL-1b secretion
restrict growth of intracellular M. kansasii. This is the first report
showing inflammasome activation induced by M. kansasii and
demonstrating a biological function for the NLRP3/ASC
inflammasome in host defense against this slow-growing NTM.
M. kansasii can cause a pneumonia that resembles classical lung
tuberculosis in many features, reflecting similarities in the
pathogenesis between M. kansasii and M. tuberculosis infection;
however, several reports have also referred to differences in host
and cellular responses to M. kansasii and M. tuberculosis. During
infection by M. tuberculosis or M. avium complex which is also a
pathogenic NTM, CD4+ T cells, interferon (IFN)-c, or IL-12p40
are crucial for the development of protective immunity in mice
[50–57]. However, CD4+ and IFN-c deficient mice display normal
resistance against pulmonary infection with M. kansasii, indicating
that a T helper cell type 1 response is not sufficient for control of
M. kansasii infection [58]. Since macrophages are the first line of
defense against pathogens such as mycobacteria, and following
phagocytosis, Mycobacterium species reside and multiply in macro-
phages, we characterized the ability of macrophages to control M.
kansasii infection in vitro. Recent studies have demonstrated that the
pathogenic mycobacteria, M. tuberculosis, M. marinum and M.
abscessus, induce activation of the NLRP3/ASC inflammasome
and subsequent release of IL-1bin macrophages [37,39–41,59,60].
Here, we found that macrophages infected by M. kansasii also
secrete IL-1b via activation of the NLRP3 inflammasome,
suggesting that all pathogenic mycobacteria may stimulate
inflammasome activation and IL-1b secretion.
The mechanisms leading to NLRP3 inflammasome activation
comprise mainly three signaling pathways, including potassium
Figure 2. Release of mature IL-1b by M. kansasii-infected cells
requires caspase-1 activation. Macrophages were infected with M.
kansasii in the presence or absence of the caspase-1 inhibitor, Z-YVAD-
FMK. At 16 h post-infection, secreted IL-1bwas quantified by ELISA (A),
and secreted caspase-1 p20 and mature IL-1b were analyzed by
Western blot analysis (B). Error bars represent standard deviations from
at least three independent experiments. ** denote a p value of ,0.001
compared to untreated infected cells.
doi:10.1371/journal.pone.0036292.g002
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efflux, cathepsin B release, and generation of ROS [30]. The
current results showed that ROS production, potassium efflux,
lysosomal acidification, and cathepsin B release are all required for
M. kansasii induced NLRP3-dependent caspase-1 activation and
IL-1b secretion. In this study, a potent cathepsin B inhibitor, CA-
074-Me, was used to determine the involvement of cathepsin B in
NLRP3 inflammasome activation during M. kansasii infection.
However, CA-074-Me has been proposed to act on other cellular
proteases [61], suggesting the possibility that CA-074-Me may
inhibit M. kansasii-induced IL-1b secretion through a cathepsin B-
independent manner. Even so, a recent study with cathepsin B
knockdown cells confirmed that cathepsin B is involved in
inflammasome activation upon mycobacteria infection [62].
It has been shown that infection by M. tuberculosis and M.
marinum may induce ESX-1-dependent NLRP3 inflammasome
activation [37,39,40,60]. ESX-1 has been identified as a critical
virulence factor in pathogenic mycobacteria and is involved in
immune signaling, cytolysis, phagosome escape and membrane
pore formation [63–67]. As M. kansasii also expresses ESX-1 [68],
it seems reasonable to assume that pore formation of cell
membranes by M. kansasii ESX-1 could cause potassium efflux
and subsequent activation of the NLRP3 inflammasome. In
addition, ESX-1-induced vacuole escape could lead to lysosomal
damage and cathepsin B release, which have been implicated as
potential activators of the NLRP3 inflammasome [63,66,67].
Recently, ESAT-6, one of the secreted effectors of ESX-1, has
been shown to be a potent activator of the NLRP3/ASC
inflammasome, possibly due to its membrane-lysing activity [39].
Genetic analysis and the nucleotide sequences revealed that the
virulence genes, esx-1 and esat-6 of M. tuberculosis, are lacking in
most environmental mycobacteria except for M. kansasii and M.
marinum [69–71], both of which can cause disease in apparently
immunocompetent persons. Moreover, analysis of immunoblot-
ting with specific antibodies indicated that the ESAT-6 was
expressed by M. kansasii [68,71]. Thus, we propose that the
activation of the NLRP3 inflammasome by live intracellular M.
kansasii might be through ESX-1 or ESAT-6.
Although the role of ROS in the activation of NLRP3
inflammasome is controversial [72–78], several studies have
demonstrated that ROS are required for inflammasome activation
during bacterial infections [42,79–82]. In this study, NAC
significantly diminished IL-1b secretion triggered by mycobacte-
rial infection, suggesting that ROS are involved in M. kansasii-
induced NLRP3 inflammasome activation; however the source of
ROS is currently unknown. The intracellular ROS are mainly
generated from two sources: the mitochondrial electron transport
chain complex, and NADPH oxidase at the plasma membrane or
phagosomal membrane of phagocytes [45,83–85]. It has been
shown that M. tuberculosis infection leads to intracellular ROS
production via NADPH oxidase at phagosomal membranes, and
Figure 3. M. kansasii induces caspase-1 activation and IL-1b secretion through the NLRP3/ASC-dependent pathway. (A) THP-1 cells
were stably transfected with shRNAs that target NLRP3 or ASC, and mRNA expression of NLRP3 and ASC was determined by RT-PCR and compared
with nontarget control (sh Ctrl) (left panel). Protein levels of NLRP3 or ASC in the respective knockdown cells were analyzed by Western blot analysis
(right panel). (B and C) NLRP3, ASC, or nontarget control (sh Ctrl) knockdown cells were infected withM. kansasii at an MOI of 10 for 16 h. Secreted IL-
1b(B) and activated caspase-1 (C) were examined by Western blot analysis.
doi:10.1371/journal.pone.0036292.g003
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ESAT-6 treatment induces a robust burst of intracellular ROS
production in human alveolar epithelial cells [86,87]. Moreover, a
low intracellular K+ concentration has been proposed to trigger
ROS generation [73], indicating the possibility that ESAT-6, a
pore-forming protein, could initiate potassium efflux and subse-
quently ROS production. Recent studies indicated that besides
NADPH oxidase, NLRX1, a member of the Nod-like receptor
(NLR) family that is localized in mitochondria, can enhance ROS
production following infections by Shigella flexneri and Chlamydia
trachomatis infection [80,88]. Moreover, mitochondrial dysfunction-
derived ROS has been shown to activate NLRP3 inflammasome
[89,90]. Thus, whether ESAT-6, NADPH oxidase, NLRX1 or
mitochondrial dysfunction are involved in M. kansasii-induced
ROS production remains to be determined.
Caspase-1, known as an inflammatory caspase, plays a key role
in the innate immune response of macrophages to various
infections [91–93]. Activation of caspase-1 is responsible for the
processing and secretion of the proinflammatory cytokines, IL-1b
and IL-18 [34,94,95]. In addition, active caspase-1 mediates either
cell death or survival, and regulates unconventional secretion of
leaderless proteins [33]. Even so, much remains to be learned
regarding the role of caspase-1 activation in the control of bacterial
infection. In cervical epithelial cells infected by C. trachomatis,
caspase-1activation contributes to the development of chlamydial
infection [81], but caspase-1-dependent caspase-7 activation
restricts Legionella pneumophila replication in macrophages and in
mice [96]. In mycobacterial infection, overexpression of caspase-1
represses M. tuberculosis growth in THP-1 macrophages [39]. In
Figure 4. Potassium efflux, lysosomal acidification, cathepsin B release and ROS production are involved in inflammasome
activation by M. kansasii. (A) Macrophages were treated with KCl and Glibenclamide (Gliben) at the indicated concentration for 30 min, and
subsequently infected with M. kansasii at an MOI of 10 for 16 h. Supernatants from infected cells were harvested and assayed for IL-1b by ELISA. (B
and C) THP-1 derived macrophages were infected with M. kansasii at an MOI of 10. N-acetyl cysteine (NAC), NH4Cl, chloroquine (CQ) and CA-074-Me
(CA-074) were added at the indicated concentration as described in Materials and Methods. Supernatants harvested at 16 h post-infection were
assayed for IL-1bsecretion by ELISA. Error bars represent standard deviations of at least three independent experiments, and significance was
calculated using a two-tailed t test. ** denote a p value of ,0.001 compared to untreated infected cells.
doi:10.1371/journal.pone.0036292.g004
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this study, inhibition of caspase-1 activity by Z-YVAD-FMK
resulted in higher bacterial growth, suggesting that caspase-1
activity is required for restriction of M. kansasii growth in
macrophages. Secretion of IL-1b is downstream from caspase-1
activation, and IL-1 has been implicated in controlling a variety of
intracellular pathogens such as Listeria, Leishmania, and M.
tuberculosis [50,51,97–100]. Our result that blocking IL-1b with
IL-1b specific neutralizing antibody led to significantly higher
levels of intracellular M. kansasii, and that treatment of infected
cells with IL-1b reduced the bacterial load, suggested that caspase-
1-dependent IL-1b secretion is critical for control of M. kansasii
infection. The secreted IL-1b might be sensed by IL-1R. Possibly,
IL-1R signaling promotes phagolysosomal maturation, which
enhances bacterial degradation and clearance, as reported by
Master et al. [38]. Concordantly, a previous study with IL-1R1
knockout mice demonstrated that blocking of IL-1-mediated
signaling reduced the ability to clear M. kansasii from the lungs
of IL-1R1 deficient mice [48]. These results highlighted the
important role of IL-1band IL-1R signaling pathway in defence
against M. kansasii infection, and provided another evidence for the
protective role of IL-1b in mycobacterial infection.
IL-1b signaling has been reported to play an important role in
the control of mycobacterial infection and granuloma formation
[38,39,47–49,99–103]. In humans, IL-1b is upregulated at the site
of mycobacterial infection, and genetic studies demonstrated an
association of polymorphisms in the IL-1 or IL-1R genes with
tuberculosis susceptibility and disease expression [104–107].
Notably, higher levels of IL-1b and NLRP3 mRNA were observed
in monocyte-derived macrophage from active tuberculosis patients
as compared with healthy subjects [39], suggesting the involve-
ment of NLRP3 inflammasome in human response to mycobac-
terial infection. Consistent with our results, the involvement of
NLRP3/ASC in controlling mycobacterial infection in vitro has
been reported [41]. However, recent studies using NLRP3-, ASC-,
or caspase-1-deficient mice demonstrated that NLRP3/ASC
inflammasome is not essential for the control of M. tuberculosis
infection in vivo [108–110], although it cannot be excluded that
potential compensatory mechanisms can overcome NLRP3/ASC
inflammasome dependence in these deficient mice [110]. Thus,
the role of NLRP3 inflammasome for antimycobacterial response
seems to be controversial. A recent study demonstrated that
NLRP3 inflammasome activation is disparate between human and
mouse during Francisella infection [111,112], indicating that the
human innate response to intracellular pathogens may be distinct
from the murine response. Accordingly, the exact role of NLRP3
inflammasome for the control of mycobacterial infection should be
carefully evaluated. Furthermore, the protective role of NLRP3
inflammasome against M. kansasii infection in vivo will be clarified
in future studies.
In conclusion, this report demonstrates that the NLRP3
inflammasome was activated by live intracellular M. kansasii
through a process involving low intracellular potassium concen-
tration, higher ROS, and active cathepsin B. As a consequence,
activated caspase-1 by inflammasome activation triggers the
processing and release of IL-1b,which is required for macrophage
immunity against M. kansasii infection (Figure 6).
Materials and Methods
Cells, Bacteria, and Chemical Reagents
THP-1 cells, a human acute monocytic leukemia cell line, were
obtained from American Type Culture Collection (ATCC) and
were cultured in RPMI 1640 complete medium (Invitrogen) with
10% heat-inactivated fetal bovine serum (HyClone) and 16
antibiotic-antimycotic (Invitrogen) at 37uC with 5% CO2 in a
humidified incubator. THP-1 stably expressing shRNA against
NLRP3, ASC, and nontarget control were obtained as previously
described [113,114]. The M. kansasii strain (ATCC12478) was
obtained from ATCC and grown at 35uC on Middlebrook 7H11
agar medium (Difco Laboratories) supplemented with 10%
OADC (oleic acid, albumin, dextrose, catalase; Becton Dickinson).
Heat-killed bacteria were prepared by incubation for 30 min at
80uC, and loss of viability was confirmed by plating on 7H11
plates [115]. Phorbol 12-myristate 13-acetate (PMA), glibencla-
mide, bafilomycin A1, and Z-YVAD-FMK were purchased from
Enzo Life Sciences. LPS (Escherichia coli serotype O111:B4),
nigericin, N-acetyl-L-cysteine (NAC), cytochalasin D, chloroquine
diphosphate, potassium chloride (KCl), ammonium chloride
(NH4Cl) and dimethyl sulfoxide (DMSO) were from Sigma-
Aldrich. The cathepsin B inhibitor, CA-074-Me, was from
Figure 5. Caspase-1 activation and IL-1b secretion restrict M.
kansasii growth. (A) THP-1 macrophages were infected with M.
kansasii at an MOI of 1 for 1 h, before treatment with 50 mM caspase-1
inhibitor (Z-YVAD-FMK) or dimethylsulfoxide (DMSO) alone as control.
Cells were then lysed and the intracellular bacterial load was quantified
at indicated time points. (B) The M. kansasii-infected macrophages (MOI
1, 1 h) were treated with neutralizing antibodies specific for IL-1bor
with exogenous IL-1b for 48 h. The intracellular bacterial CFU was then
determined. Results represent the mean 6 standard deviations of three
independent experiments. Data were analyzed by Student’s t test.
*p,0.05 compared to untreated infected cells.
doi:10.1371/journal.pone.0036292.g005
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Calbiochem. The cytotoxicity of reagents used for inhibition
studies were evaluated by using the CytoTox 96 Non-Radioactive
Cytotoxicity Assay according to the manufacturer’s instructions
(Promega) (Figure S2).
Bacterial infection of macrophages
THP-1 cells were differentiated into adherent macrophages by
overnight culture in complete medium supplemented with
500 ng/ml PMA, and allowed to rest for 2 days prior to infection.
THP-1 derived macrophages were challenged with bacterial
suspensions prepared in supplemented medium without antibiotics
at the indicated multiplicity of infection (MOI). When using
inhibitors or other reagents, cells were preincubated 60 min with
inhibitors or other reagents at the indicated concentrations before
bacterial infection.
Cytokine measurement by enzyme-linked
immunosorbent assay (ELISA)
To determine IL-1b levels in supernatants from M. kansasii-
infected cells, the DuoSet ELISA development system kit (R&D
Systems) for human IL-1b was used according to the manufac-
turer’s directions. ELISA plates were analyzed using an Emax
Microplate Reader (Molecular Devices) at 450 nm.
Western blotting
Cell culture supernatants from infected macrophages were
resolved on 12% SDS-polyacrylamide gels and electrotransferred
onto the polyvinylidene difluoride membranes (Millipore). For
detection of the active caspase-1 subunit (p20), the membranes
were probed with 1:1000 diluted rabbit anti-human caspase-1
antibody (Millipore) and 1:10000 diluted horseradish peroxidase-
conjugated anti-rabbit IgG antibodies (Santa Cruz Biotechnology).
For detection of pro-IL1b and mature IL-1b (p17), the blot was
probed with 1:1000 rabbit anti-human IL-1b antibody (Santa
Cruz Biotechnology) and cleaved IL-1b antibody (Cell Signaling),
respectively. To detect NLRP3 and ASC, the blots were probed
with 1:1000 rabbit anti-human NLRP3 antibody (Sigma) and
mouse anti-human ASC antibody (Santa Cruz Biotechnology),
respectively. The signals on the blots were visualized using the
enhanced chemiluminescence system (Millipore).
RNA isolation and PCR
Total RNA was isolated using the Total RNA Mini Kit
(Geneaid), reverse transcribed into cDNA (Superscript III,
Invitrogen) and analyzed for NLRP3 and ASC mRNA expression
by RT-PCR using the following primer pairs. The primers for
human GAPDH were 59-AACGGATTTGGTCGTATTGGGC-
39 forward and 59-CTTGACGGTGCCATGGAATTTG-39 re-
verse. Primers for human NLRP3 were 59-CTTCTCTGATGA-
GGCCCAAG-39 forward and 59-GCAGCAAACTGGAAAG-
GAAG-39 reverse. Primers for human ASC were 59-ATCCA-
GGCCCCTCCTCAGT-39 forward and 59-GTTTGTGACC-
CTCGCGATAAG-39 reverse.
Evaluation of intracellular bacterial viability by the
Colony Forming Unit assay
THP-1 cells (56105 cells/well) were added to 24-well plates and
differentiated into macrophages with PMA. Monolayers of
macrophages were infected by M. kansasii at an MOI of 1. After
1 h, the medium was removed and the wells were washed with
serum-free medium to remove extracellular bacteria and then
fresh medium was added. The infected cells were further
incubated at 37uC for the indicated time. Some of the infected
Figure 6. NLRP3/ASC inflammasome activation restrictsMycobacterium kansasii infection. DuringM. kansasii infection, live and intracellular
bacteria trigger potassium efflux, ROS production and lysosomal damage with cathepsin B release (1), and then lead to NLRP3/ASC inflammasome
activation, resulting caspase-1 activation and IL-1bsecretion (2). IL-1b derived from inflammasome activation is released and followed by the
engagement of its receptor (IL-1R) (3). IL-1R signaling promotes phagosome maturation that ultimately leads to phagolysosome fusion and bacterial
degradation (4).
doi:10.1371/journal.pone.0036292.g006
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cells were treated with caspase-1 inhibitor, IL-1b neutralizing
antibody (R&D Systems) or exogenous IL-1b (R&D Systems) for
different time intervals as described. To evaluate the intracellular
bacterial load, cells were lysed with 500 ml of sterile water with
0.1% triton X-100, and the number of viable intracellular bacteria
was counted by plating serial dilutions of the lysis solution onto
Middlebrook 7H11 agar plates.
Statistical analysis
All experiments were performed at least three times, and the
results are presented as the mean 6 standard deviation (SD).
Statistical comparisons were performed using Student’s t test.
Supporting Information
Figure S1 IL-6 production is unimpaired in NLRP3 or
ASC knockdown cells. To determine whether the ability to
generate pro-IL-1b in response to LPS is diminished in NLRP3 or
ASC knockdown cells. ASC, NLRP3, or nontarget control (sh
Ctrl) knockdown cells were treated with 1 mg/ml LPS or M.
kansasii at an MOI of 10. IL-6 in supernatant was measured by
ELISA (R&D Systems). Values represent the mean 6 standard
deviations of at least three independent experiments. These results
indicated that ASC and NLRP3 knockdown cells can produce IL-
6 normally in response to LPS or M. kansasii.
(TIF)
Figure S2 No apparent cytotoxic effects of inhibitors on
THP-1 cells in the experimental conditions. To evaluate
cytotoxic effects of inhibitors used in this study, THP-1 derived
macrophages were treated with the indicated pharmacological
inhibitors. Cytotoxicity was quantitated by measurement of lactate
dehydrogenase (LDH) activity in the culture supernatants using a
CytoTox 96 assay kit (Promega) according to the manufacturer’s
protocol. Error bars represent standard deviation of at least three
independent experiments. These results indicated that the
experimental treatments have no apparent cytotoxic effects.
(TIF)
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